AT540978T - Human monoclonal antibody against CD20 - Google Patents

Human monoclonal antibody against CD20

Info

Publication number
AT540978T
AT540978T AT03809145T AT03809145T AT540978T AT 540978 T AT540978 T AT 540978T AT 03809145 T AT03809145 T AT 03809145T AT 03809145 T AT03809145 T AT 03809145T AT 540978 T AT540978 T AT 540978T
Authority
AT
Austria
Prior art keywords
monoclonal antibody
antibody against
human monoclonal
against cd20
cd20
Prior art date
Application number
AT03809145T
Other languages
German (de)
Inventor
Jessica Teeling
Sigrid Ruuls
Martin Glennie
De Winkel Jan Van
Paul Parren
Jorgen Petersen
Ole Baadsgaard
Haichun Huang
Original Assignee
Genmab As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
Priority to US41916302P priority Critical
Priority to US46002803P priority
Application filed by Genmab As filed Critical Genmab As
Priority to PCT/US2003/033057 priority patent/WO2004035607A2/en
Publication of AT540978T publication Critical patent/AT540978T/en
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32110219&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AT540978(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • C07K16/4258Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854Immunoglobulins
    • G01N33/686Anti-idiotype
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54F(ab')2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72Increased effector function due to an Fc-modification
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732Antibody-dependent cellular cytotoxicity [ADCC]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734Complement-dependent cytotoxicity [CDC]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
AT03809145T 2002-10-17 2003-10-17 Human monoclonal antibody against CD20 AT540978T (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US41916302P true 2002-10-17 2002-10-17
US46002803P true 2003-04-02 2003-04-02
PCT/US2003/033057 WO2004035607A2 (en) 2002-10-17 2003-10-17 Human monoclonal antibodies against cd20

Publications (1)

Publication Number Publication Date
AT540978T true AT540978T (en) 2012-01-15

Family

ID=32110219

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03809145T AT540978T (en) 2002-10-17 2003-10-17 Human monoclonal antibody against CD20

Country Status (22)

Country Link
US (2) US8529902B2 (en)
EP (4) EP1558648B1 (en)
JP (3) JP4662473B2 (en)
KR (7) KR100932340B1 (en)
CN (3) CN103709250B (en)
AT (1) AT540978T (en)
AU (1) AU2003301445A1 (en)
BR (2) BR0315295A (en)
CA (2) CA2502552C (en)
CY (1) CY1112750T1 (en)
DK (1) DK1558648T3 (en)
EA (2) EA021644B1 (en)
ES (2) ES2380621T3 (en)
HK (1) HK1077590A1 (en)
IL (2) IL167851A (en)
LU (1) LU92041I9 (en)
MX (1) MXPA05004022A (en)
NZ (2) NZ568769A (en)
PL (2) PL216630B1 (en)
PT (1) PT1558648E (en)
SI (1) SI1558648T1 (en)
WO (1) WO2004035607A2 (en)

Families Citing this family (248)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7744877B2 (en) * 1992-11-13 2010-06-29 Biogen Idec Inc. Expression and use of anti-CD20 Antibodies
EP1005870B1 (en) * 1992-11-13 2009-01-21 Biogen Idec Inc. Therapeutic application of chimeric antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
CN101695574A (en) 1998-08-11 2010-04-21 拜奥根Idec公司; Combination therapies for b-cell lymphomas comprising administration of anti-cd20 antibody
AU761516B2 (en) * 1998-11-09 2003-06-05 Biogen Inc. Chimeric anti-CD20 antibody treatment of patients receiving BMT or PBSC transplants
JP4842435B2 (en) * 1998-11-09 2011-12-21 バイオジェン・アイデック・インコーポレイテッドBiogen Idec Inc. Treatment of hematological malignancies associated with circulating tumor cells using chimeric anti-CD20 antibodies
US8557244B1 (en) 1999-08-11 2013-10-15 Biogen Idec Inc. Treatment of aggressive non-Hodgkins lymphoma with anti-CD20 antibody
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
WO2006085967A2 (en) * 2004-07-09 2006-08-17 Xencor, Inc. OPTIMIZED ANTI-CD20 MONOCONAL ANTIBODIES HAVING Fc VARIANTS
EP1558648B1 (en) 2002-10-17 2012-01-11 Genmab A/S Human monoclonal antibodies against cd20
DE10254601A1 (en) 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Differentially expressed in tumors gene products and their use
WO2004056312A2 (en) 2002-12-16 2004-07-08 Genentech, Inc. Immunoglobulin variants and uses thereof
CA2525251C (en) * 2003-05-09 2015-10-27 Duke University Cd20-specific antibodies and methods employing same
AR044388A1 (en) 2003-05-20 2005-09-07 Applied Molecular Evolution CD20 binding molecules
US20050053602A1 (en) * 2003-08-29 2005-03-10 Genentech, Inc. Therapy of ocular disorders
NZ547589A (en) 2003-11-05 2009-05-31 Glycart Biotechnology Ag CD20 antibodies with increased Fc receptor binding affinity and effector function
FR2867982B1 (en) * 2004-03-26 2007-07-20 Jean Marie Andrieu Method for enhancing the activity of therapeutic vaccines
EP1742660A2 (en) * 2004-04-16 2007-01-17 Genentech, Inc. Treatment of disorders
BRPI0508762A (en) * 2004-04-16 2007-08-14 Genentech Inc method of increasing the B cell depletion in mammals method of enhancing the efficacy of B cell depletion, malignancy method of treating or neoplasms of B cells relief method autoimunológica dysfunction regulated by B cell depletion method of b cell composition
WO2005108989A2 (en) * 2004-04-16 2005-11-17 Genentech, Inc. Assay for antibodies
WO2005103081A2 (en) * 2004-04-20 2005-11-03 Genmab A/S Human monoclonal antibodies against cd20
BRPI0510224A (en) * 2004-05-05 2007-10-23 Genentech Inc methods of preventing disease and industrial autoimunológica Article
DE102004024617A1 (en) 2004-05-18 2005-12-29 Ganymed Pharmaceuticals Ag Differentially expressed in tumors gene products and their use
CA2566979A1 (en) * 2004-06-04 2005-12-15 Genentech, Inc. Use of a cd20 antibody in treatment of multiple sclerosis
CA2570213C (en) * 2004-07-02 2014-02-18 The Walter And Eliza Hall Institute Of Medical Research Alpha-helical mimetics
EA012464B1 (en) 2004-08-04 2009-10-30 Эпплайд Молекьюлар Эволюшн, Инк. Antibody against cd20 and its application
CA2580271A1 (en) * 2004-10-05 2006-04-20 Genentech, Inc. Method for treating vasculitis
JO3000B1 (en) 2004-10-20 2016-09-05 Genentech Inc Antibody Formulations.
FR2879204B1 (en) 2004-12-15 2007-02-16 Lab Francais Du Fractionnement cytotoxic antibody directed against the lymphoid proliferations haematopoietic type b.
EP2261257B1 (en) * 2005-01-12 2018-07-11 Proteonova, Inc. Method for making targeted therapeutic agents
US10206998B2 (en) 2005-01-12 2019-02-19 Proteonova, Inc. Modular targeted therapeutic agents and methods of making same
JP5225069B2 (en) * 2005-03-23 2013-07-03 ゲンマブ エー/エス Antibodies against CD38 for the treatment of multiple myeloma
AR053579A1 (en) * 2005-04-15 2007-05-09 Genentech Inc Treatment of inflammatory bowel disease (IBD)
JP5224707B2 (en) * 2005-04-28 2013-07-03 持田製薬株式会社 Anti-platelet membrane glycoprotein VI monoclonal antibody
WO2006117910A1 (en) 2005-04-28 2006-11-09 Mochida Pharmaceutical Co., Ltd. Monoclonal antibody against platelet membrane glycoprotein vi
FR2886298A1 (en) * 2005-05-24 2006-12-01 Ifremer Antibody or antibody fragment has a couple immunogen
US20110129412A1 (en) * 2005-06-02 2011-06-02 Astrazeneca Ab Antibodies Directed to CD20 and Uses Thereof
AU2006272204A1 (en) 2005-07-21 2007-01-25 Genmab A/S Potency assays for antibody drug substance binding to an Fc receptor
CA2616395C (en) 2005-07-25 2016-10-04 Trubion Pharmaceuticals B-cell reduction using cd37-specific and cd20-specific binding molecules
US20090215992A1 (en) * 2005-08-19 2009-08-27 Chengbin Wu Dual variable domain immunoglobulin and uses thereof
EP1762575A1 (en) 2005-09-12 2007-03-14 Ganymed Pharmaceuticals AG Identification of tumor-associated antigens for diagnosis and therapy
US9726673B2 (en) 2005-11-23 2017-08-08 Genentech, Inc. Methods and compositions related to B cell assays
EP1790664A1 (en) 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoclonal antibodies against claudin-18 for treatment of cancer
TWI461436B (en) 2005-11-25 2014-11-21 Kyowa Hakko Kirin Co Ltd Human monoclonal antibody human cd134 (ox40) and methods of making and using same
TWI390034B (en) 2006-04-06 2013-03-21 Kyowa Hakko Kirin Co Ltd
MX363905B (en) 2006-06-12 2019-04-08 Aptevo Res And Development Llc Single-chain multivalent binding proteins with effector function.
WO2008003319A1 (en) 2006-07-04 2008-01-10 Genmab A/S Cd20 binding molecules for the treatment of copd
WO2008037257A2 (en) 2006-09-26 2008-04-03 Genmab A/S Anti-cd38 plus corticosteroids plus a non-corticosteroid chemotherapeutic for treating tumors
EP2486941B1 (en) * 2006-10-02 2017-03-15 E. R. Squibb & Sons, L.L.C. Human antibodies that bind CXCR4 and uses thereof
US9382327B2 (en) * 2006-10-10 2016-07-05 Vaccinex, Inc. Anti-CD20 antibodies and methods of use
NZ577933A (en) 2007-01-22 2011-12-22 Genentech Inc Polyelectrolyte precipitation and purification of antibodies
EP1970384A1 (en) 2007-03-14 2008-09-17 Ganymed Pharmaceuticals AG Monoclonal antibodies for treatment of cancer
PE01902009A1 (en) * 2007-03-23 2009-03-22 Smithkline Beecham Corp Combination of anti-CD20 antibodies and polypeptides of IL-18
US7960139B2 (en) 2007-03-23 2011-06-14 Academia Sinica Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells
CA2681974A1 (en) 2007-03-29 2008-10-09 Genmab A/S Bispecific antibodies and methods for production thereof
EP1997832A1 (en) 2007-05-29 2008-12-03 Ganymed Pharmaceuticals AG Monoclonal antibodies against Claudin-18 for treatment of cancer
EP3406263A1 (en) 2007-05-29 2018-11-28 Novartis AG New indications for anti-il-1beta therapy
EP2167669A2 (en) 2007-05-31 2010-03-31 Genmab A/S Transgenic animals producing monovalent human antibodies and antibodies obtainable from these animals
WO2009009407A1 (en) 2007-07-06 2009-01-15 Smithkline Beecham Corporation Antibody formulations
US7879984B2 (en) 2007-07-31 2011-02-01 Regeneron Pharmaceuticals, Inc. Human antibodies to human CD20 and method of using thereof
RU2595383C2 (en) 2007-09-05 2016-08-27 Ф.Хоффманн-Ля Рош Аг Combined therapy with anti-cd20 antibodies type i and type ii
US20090098118A1 (en) 2007-10-15 2009-04-16 Thomas Friess Combination therapy of a type ii anti-cd20 antibody with an anti-bcl-2 active agent
HUE030134T2 (en) 2007-10-16 2017-04-28 Zymogenetics Inc Combination of transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI) and anti-CD20 agents for treatment of autoimmune disease
US20110091473A1 (en) * 2007-10-22 2011-04-21 Genmab A/S Novel antibody therapies
DK2840090T3 (en) 2007-10-30 2018-04-23 Genentech Inc Antibody purification by cation exchange chromatography
JP2011507897A (en) * 2007-12-21 2011-03-10 ジェネンテック, インコーポレイテッド Treatment of rituximab-resistant patients with rheumatoid arthritis
US7914785B2 (en) 2008-01-02 2011-03-29 Bergen Teknologieverforing As B-cell depleting agents, like anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome
EP2077281A1 (en) 2008-01-02 2009-07-08 Bergen Teknologioverforing AS Anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome
RU2589704C2 (en) 2008-03-25 2016-07-10 Роше Гликарт Аг Using anti-cd20 type ii antibody, having high antibody-induced cell-dependent cytotoxicity (adcc), combined with cyclophosphamide, vincristine and doxorubicin for treating non-hodgkin lymphomas
ES2368700T3 (en) 2008-04-11 2011-11-21 Emergent Product Development Seattle, Llc and CD37 immunotherapeutic agent for combination with a bifunctional chemotherapeutic agent thereof.
US20090269339A1 (en) * 2008-04-29 2009-10-29 Genentech, Inc. Responses to immunizations in rheumatoid arthritis patients treated with a cd20 antibody
EP2318832B1 (en) 2008-07-15 2013-10-09 Academia Sinica Glycan arrays on ptfe-like aluminum coated glass slides and related methods
WO2011011027A1 (en) 2009-07-20 2011-01-27 Bristol-Myers Squibb Company Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases
WO2010014784A2 (en) 2008-08-01 2010-02-04 Bristol-Myers Squibb Company Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases
US20120122759A1 (en) 2008-08-14 2012-05-17 Arick Brown Methods for removing a contaminant using indigenous protein displacement ion exchange membrane chromatography
EP2334323A2 (en) 2008-09-10 2011-06-22 F.Hoffmann-La Roche Ag Compositions and methods for the prevention of oxidative degradation of proteins
EP2166021A1 (en) 2008-09-16 2010-03-24 Ganymed Pharmaceuticals AG Monoclonal antibodies for treatment of cancer
TW201438738A (en) 2008-09-16 2014-10-16 Genentech Inc Methods for treating progressive multiple sclerosis
WO2010042433A1 (en) 2008-10-06 2010-04-15 Bristol-Myers Squibb Company Combination of cd137 antibody and ctla-4 antibody for the treatment of proliferative diseases
EP2373687B1 (en) 2008-12-03 2016-10-26 Genmab A/S Igg4 antibody variants having modifications in the constant region
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
EP2373339B1 (en) * 2009-01-06 2017-04-19 INSERM (Institut National de la Santé et de la Recherche Médicale) A b cell depleting agent for the treatment of atherosclerosis
MX2011007589A (en) * 2009-01-16 2011-08-17 Glaxosmithkline Llc Treatment of a cancer using a combination of bendamustine and an anti-cd20 antibody.
BRPI1008564A2 (en) 2009-02-20 2018-02-27 Ganymed Pharmaceuticals Ag methods and compositions for cancer diagnosis and treatment
AR075982A1 (en) * 2009-03-31 2011-05-11 Roche Glycart Ag A combination therapy afucosilado antibody and one or more cytokines selected from GM- CSF, m -CSF human and / or human IL-3 and composition
TWI409079B (en) 2009-08-14 2013-09-21 Roche Glycart Ag Combination therapy of an afucosylated cd20 antibody with bendamustine
CA2769595A1 (en) 2009-08-14 2011-02-17 Roche Glycart Ag Combination therapy of an afucosylated cd20 antibody with fludarabine and/or mitoxantrone
US8728730B2 (en) 2009-09-03 2014-05-20 Genentech, Inc. Methods for treating, diagnosing, and monitoring rheumatoid arthritis
AR078161A1 (en) 2009-09-11 2011-10-19 Hoffmann La Roche highly concentrated anti-CD20 antibody of pharmaceutical formulations. Use of the formulation. treatment method.
US20110070227A1 (en) * 2009-09-18 2011-03-24 Anna-Marie Novotney-Barry Treatment of Autoimmune and Inflammatory Diseases
WO2011057188A1 (en) 2009-11-06 2011-05-12 Idexx Laboratories, Inc. Canine anti-cd20 antibodies
PT2499161T (en) 2009-11-11 2017-12-05 Johannes Gutenberg-Universität Mainz Antibodies specific for claudin 6 (cldn6)
EP2322555A1 (en) 2009-11-11 2011-05-18 Ganymed Pharmaceuticals AG Antibodies specific for claudin 6 (CLDN6)
US10087236B2 (en) 2009-12-02 2018-10-02 Academia Sinica Methods for modifying human antibodies by glycan engineering
JP5841072B2 (en) * 2010-02-10 2016-01-06 イミュノジェン・インコーポレーテッド CD20 antibody and use thereof
AR080155A1 (en) * 2010-02-10 2012-03-14 Immunogen Inc anti-CD20 antibodies and their use
CN104998269B (en) 2010-03-22 2019-06-11 弗·哈夫曼-拉罗切有限公司 For stablizing the preparation containing protein useful composition and method
EP2371864A1 (en) 2010-03-23 2011-10-05 Ganymed Pharmaceuticals AG Monoclonal antibodies for treatment of cancer
WO2011130332A1 (en) 2010-04-12 2011-10-20 Academia Sinica Glycan arrays for high throughput screening of viruses
CA2832389A1 (en) 2011-04-20 2012-10-26 Genmab A/S Bispecific antibodies against her2 and cd3
CN110066339A (en) 2010-04-20 2019-07-30 根马布股份公司 Albumen of the FC containing heterodimeric antibodies and preparation method thereof
WO2012143523A1 (en) 2011-04-20 2012-10-26 Genmab A/S Bispecifc antibodies against her2
CN102844049B (en) 2010-04-27 2016-06-01 罗切格利卡特公司 None of fucosylated CD20 antibody combination therapy with inhibitors of mTOR
KR20130060227A (en) 2010-05-03 2013-06-07 제넨테크, 인크. Compositions and methods useful for reducing the viscosity of protein-containing formulations
DK2975409T3 (en) 2010-05-10 2018-12-17 Acad Sinica Zanamivir phosphonate congeners with anti-influenza activity and determination of oseltamivir sensitivity in influenza viruses
WO2011146382A1 (en) 2010-05-17 2011-11-24 Bristol-Myers Squibb Company Improved immunotherapeutic dosing regimens and combinations thereof
EP2580243A1 (en) 2010-06-09 2013-04-17 Genmab A/S Antibodies against human cd38
AU2011270828B2 (en) 2010-06-24 2015-09-24 Genentech, Inc. Compositions and methods containing alkylgycosides for stabilizing protein- containing formulations
EP2404936A1 (en) 2010-07-06 2012-01-11 Ganymed Pharmaceuticals AG Cancer therapy using CLDN6 target-directed antibodies in vivo
WO2012018771A1 (en) 2010-08-03 2012-02-09 Genentech, Inc. Chronic lymphocytic leukemia (cll) biomarkers
WO2012019168A2 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
TW201208703A (en) 2010-08-17 2012-03-01 Roche Glycart Ag Combination therapy of an afucosylated CD20 antibody with an anti-VEGF antibody
CA2821992A1 (en) 2010-10-01 2012-04-05 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
TWI603738B (en) 2010-11-08 2017-11-01 Genentech Inc Subcutaneously anti-receptor antibody-6 -il
JP6157045B2 (en) * 2010-12-06 2017-07-05 公益財団法人がん研究会 CD20-recognizing monoclonal antibody, hybridoma, CD20 detection method and determination method
MX2013006739A (en) 2010-12-16 2013-07-17 Roche Glycart Ag Combination therapy of an afucosylated cd20 antibody with a mdm2 inhibitor.
JP2014506258A (en) * 2011-01-10 2014-03-13 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited New use
JP6271254B2 (en) 2011-02-28 2018-01-31 ジェネンテック, インコーポレイテッド Methods for predicting biological markers and responses to B cell antagonists
US8710200B2 (en) 2011-03-31 2014-04-29 Moderna Therapeutics, Inc. Engineered nucleic acids encoding a modified erythropoietin and their expression
UA115969C2 (en) 2011-05-13 2018-01-25 Ганімед Фармасьютікалз Аг Antibodies for treatment of cancer expressing claudin 6
NZ703939A (en) 2011-05-21 2016-01-29 Macrogenics Inc Cd3-binding molecules capable of binding to human and non-human cd3
EP2537933A1 (en) 2011-06-24 2012-12-26 Institut National de la Santé et de la Recherche Médicale (INSERM) An IL-15 and IL-15Ralpha sushi domain based immunocytokines
BR112014000264A2 (en) 2011-07-06 2017-02-14 Genmab B V methods for increasing and decreasing an effector function of a parental polypeptide and a parent antibody, for enhancing an effector function of a combination of at least one first and a second parent polypeptide, for inducing an effector response against a cell, cell membrane, or virion, to increase the specificity of a combination of at least a first and a second parent polypeptide, variant of a parent polypeptide, composition, and part kit
AU2012280267B2 (en) 2011-07-06 2016-04-21 Morphosys Ag Therapeutic combinations of anti-cd20 and anti-gm-csf antibodies and uses thereof
US10323081B2 (en) 2011-07-06 2019-06-18 Genmag A/S Modulation of complement-dependent cytotoxicity through modifications of the C-terminus of antibody heavy chains
BR112015000167A2 (en) 2012-07-06 2017-08-08 Genmab B V dimeric protein, oligomer, hexamer, composition, methods for enhancing solution oligomerization and / or an effector function of a dimeric protein, for treating a bacterial, viral or parasitic infection, for imaging at least a part of the human body or another mammal, or to modulate clearance of a target molecule from the body of a human or other mammal and to prevent or treat a disease, variant dimeric protein, and kit of parts
CN102875678B (en) * 2011-07-13 2014-08-06 无锡天演生物技术有限公司 Human anti-human CD20 monoclonal antibody molecule and application thereof
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
CN107056936A (en) * 2011-09-19 2017-08-18 科马布有限公司 Manipulation of immunoglobulin gene diversity and multi-antibody therapeutic agent
CN110201187A (en) 2011-12-16 2019-09-06 现代泰克斯公司 Modified nucleosides, nucleotide and nucleic acid compositions
NZ623476A (en) 2011-10-03 2016-09-30 Moderna Therapeutics Inc Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
AU2012328819B2 (en) 2011-10-26 2017-08-03 Elanco Tiergesundheit Ag Monoclonal antibodies and methods of use
DK2771364T3 (en) 2011-10-27 2019-08-19 Genmab As Preparation of heterodimered proteins
US20130302274A1 (en) 2011-11-25 2013-11-14 Roche Glycart Ag Combination therapy
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
SG11201403437TA (en) 2011-12-22 2014-07-30 Genentech Inc Ion exchange membrane chromatography
TW201334789A (en) 2012-01-31 2013-09-01 Genentech Inc Anti-IgE antibodies and methods using same
CN102585000B (en) * 2012-02-22 2013-05-29 尉军 Tumor marker CD25 autoantibody and application thereof
US20150110779A1 (en) 2012-03-15 2015-04-23 Bristol-Myers Squibb Company Methods for predicting gastrointestinal immune-related adverse events (gi-irae) in patients treated with modulation of the co-stimulatory pathway
US20150064235A1 (en) 2012-03-30 2015-03-05 Moderna Therapeutics, Inc. Modified polynucleotides
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
CA2869005A1 (en) 2012-04-02 2013-10-10 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins associated with human disease
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
US10130714B2 (en) 2012-04-14 2018-11-20 Academia Sinica Enhanced anti-influenza agents conjugated with anti-inflammatory activity
PL2662386T3 (en) 2012-05-07 2019-08-30 Astellas Pharma Inc. Antibodies that bind to PLAC1 and block interaction between PLAC1 and FGF7
WO2013167153A1 (en) 2012-05-09 2013-11-14 Ganymed Pharmaceuticals Ag Antibodies useful in cancer diagnosis
US20150118244A1 (en) 2012-05-10 2015-04-30 Bristol-Myers Squibb Company Anti-tumor antibodies as predictive or prognostic biomarkers of efficacy and survival in ipilimumab-treated patients
TR201810930T4 (en) 2012-05-18 2018-08-27 Genentech Inc High concentrations of monoclonal antibody formulations.
EP3254695A1 (en) 2012-05-23 2017-12-13 GANYMED Pharmaceuticals AG Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
WO2013174403A1 (en) 2012-05-23 2013-11-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
WO2013174404A1 (en) 2012-05-23 2013-11-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
SG11201510739TA (en) 2013-07-05 2016-01-28 Genmab As Humanized or chimeric cd3 antibodies
CN103588882B (en) * 2012-08-13 2015-10-28 中国抗体制药有限公司 Idiotype antibodies against human cd22 antibody and its application
AU2013306098A1 (en) 2012-08-18 2015-02-12 Academia Sinica Cell-permeable probes for identification and imaging of sialidases
US9547009B2 (en) 2012-08-21 2017-01-17 Academia Sinica Benzocyclooctyne compounds and uses thereof
US8643360B1 (en) * 2012-09-02 2014-02-04 George S. Cargill, III In-water voltage gradient detector
AR092612A1 (en) 2012-09-21 2015-04-29 Regeneron Pharma anti-CD3 antibodies, bispecific binding molecules that bind antigen CD3 and CD20, and uses thereof
US9714291B2 (en) 2012-10-05 2017-07-25 Kyowa Hakko Kirin Co., Ltd Heterodimer protein composition
US9492563B2 (en) 2012-10-30 2016-11-15 Esperance Pharmaceuticals, Inc. Antibody/drug conjugates and methods of use
WO2014075697A1 (en) 2012-11-13 2014-05-22 Biontech Ag Agents for treatment of claudin expressing cancer diseases
CA2890438A1 (en) 2012-11-13 2014-05-22 Biontech Ag Agents for treatment of claudin expressing cancer diseases
US9597380B2 (en) 2012-11-26 2017-03-21 Modernatx, Inc. Terminally modified RNA
CN103173412B (en) * 2012-12-07 2015-04-22 天津三箭生物技术有限公司 Mouse anti-human CD20 monoclonal antibody and hybridoma cell strain for secreting monoclonal antibody
AU2013372331A1 (en) 2013-01-10 2015-07-23 Genmab B.V. Human IgG1 Fc region variants and uses thereof
CN103145847B (en) * 2013-02-05 2014-05-21 浙江大学 Anti-CD20 antibody-monomethyl auristatin E conjugate, preparation method and application thereof
WO2014127785A1 (en) 2013-02-20 2014-08-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
SG11201507475UA (en) 2013-03-13 2015-10-29 Genentech Inc Antibody formulations
FR3003171B1 (en) * 2013-03-15 2015-04-10 Lab Francais Du Fractionnement Novel medicaments comprising an enhanced antibody composition in majority load enforcement
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
WO2014146672A1 (en) 2013-03-18 2014-09-25 Ganymed Pharmaceuticals Ag Therapy involving antibodies against claudin 18.2 for treatment of cancer
CN103254317B (en) * 2013-05-08 2014-08-13 浙江大学 Anti-CD20 monoclonal antibody-aplysiatoxin conjugate as well as preparation method and application thereof
EP3013365B1 (en) 2013-06-26 2019-06-05 Academia Sinica Rm2 antigens and use thereof
US9981030B2 (en) 2013-06-27 2018-05-29 Academia Sinica Glycan conjugates and use thereof
EA031080B1 (en) 2013-08-08 2018-11-30 Ситюн Фарма IL-15 AND IL-15Rα SUSHI DOMAIN BASED MODULOKINES
CN103467605B (en) * 2013-09-05 2015-02-04 武汉友芝友生物制药有限公司 CD3 antigen and preparation method and application thereof
WO2015035337A1 (en) 2013-09-06 2015-03-12 Academia Sinica HUMAN iNKT CELL ACTIVATION USING GLYCOLIPIDS WITH ALTERED GLYCOSYL GROUPS
MX2016004249A (en) 2013-10-03 2016-11-08 Moderna Therapeutics Inc Polynucleotides encoding low density lipoprotein receptor.
WO2015069703A1 (en) 2013-11-06 2015-05-14 Bristol-Myers Squibb Company Immunotherapeutic dosing regimens and combinations thereof
WO2015067586A2 (en) * 2013-11-07 2015-05-14 F. Hoffmann-La Roche Ag Combination therapy of an anti cd20 antibody with a btk inhibitor
SG11201604875PA (en) 2013-12-17 2016-07-28 Genentech Inc Methods of treating cancer using pd-1 axis binding antagonists and an anti-cd20 antibody
KR20170128222A (en) * 2015-01-08 2017-11-22 젠맵 에이/에스 Antibodies against CD3 and CD20
US9975965B2 (en) 2015-01-16 2018-05-22 Academia Sinica Compositions and methods for treatment and detection of cancers
US10150818B2 (en) 2014-01-16 2018-12-11 Academia Sinica Compositions and methods for treatment and detection of cancers
US10118969B2 (en) 2014-05-27 2018-11-06 Academia Sinica Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
TW201620939A (en) 2014-01-16 2016-06-16 Academia Sinica Treating cancer and combinations thereof, and methods of detecting
EP2910645A1 (en) 2014-02-25 2015-08-26 STRATIFYER Molecular Pathology GmbH Methods and compositions for prediction of therapeutic efficacy of cancer treatments and cancer prognosis upon antibody treatment
CN106415244A (en) 2014-03-27 2017-02-15 中央研究院 Reactive labelling compounds and uses thereof
CN103880958B (en) * 2014-03-27 2016-01-20 安徽大学 L4h6 anti-cd20 antibody antigen and its application
CN103880957B (en) * 2014-03-27 2016-01-20 安徽大学 L1h1 anti-cd20 antibody antigen and its application
AU2015267045A1 (en) 2014-05-27 2017-01-05 Academia Sinica Anti-HER2 glycoantibodies and uses thereof
CN106661562A (en) 2014-05-27 2017-05-10 中央研究院 Fucosidase from bacteroides and methods using the same
KR20170042802A (en) 2014-09-08 2017-04-19 아카데미아 시니카 HUMAN iNKT CELL ACTIVATION USING GLYCOLIPIDS
CN107249632A (en) 2014-12-04 2017-10-13 百时美施贵宝公司 Combination of anti-CS1 and anti-PD1 antibodies to treat cancer (myeloma)
WO2016097300A1 (en) 2014-12-19 2016-06-23 Genmab A/S Rodent bispecific heterodimeric proteins
WO2016118191A1 (en) 2015-01-24 2016-07-28 Academia Sinica Novel glycan conjugates and methods of use thereof
US20180215801A1 (en) 2015-01-29 2018-08-02 Board Of Trustees Of Michigan State University Cryptic polypeptides and uses thereof
US20190175748A1 (en) 2016-03-16 2019-06-13 Amal Therapeutics Sa Combination of an immune checkpoint modulator and a complex comprising a cell penetrating peptide, a cargo and a tlr peptide agonist for use in medicine
WO2016146143A1 (en) 2015-03-16 2016-09-22 Amal Therapeutics Sa Cell penetrating peptides and complexes comprising the same
EP3273974A4 (en) 2015-03-26 2018-11-07 Women and Infants Hospital of Rhode Island Inc. Therapy for malignant disease
WO2016165765A1 (en) 2015-04-15 2016-10-20 Ganymed Pharmaceuticals Ag Methods and compositions for prediction of therapeutic efficacy of cancer treatments and cancer prognosis
WO2016165762A1 (en) 2015-04-15 2016-10-20 Ganymed Pharmaceuticals Ag Drug conjugates comprising antibodies against claudin 18.2
KR20180015195A (en) 2015-06-03 2018-02-12 보스톤 바이오메디칼, 인크. Composition comprising a cancer stem function inhibitor and an immunotherapeutic agent for use in the treatment of cancer
EP3108897A1 (en) 2015-06-24 2016-12-28 F. Hoffmann-La Roche AG Antibodies against human csf-1r for use in inducing lymphocytosis in lymphomas or leukemias
JP2018522881A (en) 2015-06-29 2018-08-16 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company Immunotherapy administration regimens and combinations thereof
BR112017027736A2 (en) 2015-06-29 2018-10-09 Genentech Inc anti-cd20 type ii antibody for use in organ transplantation
US20180201693A1 (en) 2015-07-09 2018-07-19 Genmab A/S Bispecific and multispecific antibodies and method for isolation of such
US20180140660A1 (en) 2015-07-16 2018-05-24 Biokine Therapeutics Ltd. Compositions and methods for treating cancer
EP3331919A1 (en) 2015-08-07 2018-06-13 GlaxoSmithKline Intellectual Property Development Limited Combination therapy comprising anti ctla-4 antibodies
EP3334747A1 (en) 2015-08-13 2018-06-20 Amgen Inc. Charged depth filtration of antigen-binding proteins
CR20180149A (en) 2015-10-02 2018-04-05 Hoffmann La Roche bispecific antibodies against human CD20 and the human transferrin receptor and methods of use
EP3252078A1 (en) 2016-06-02 2017-12-06 F. Hoffmann-La Roche AG Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer
EP3178848A1 (en) 2015-12-09 2017-06-14 F. Hoffmann-La Roche AG Type ii anti-cd20 antibody for reducing formation of anti-drug antibodies
CN105348388B (en) * 2015-12-11 2018-10-19 安徽大学 The antibody L3H3 of anti-CD20 antigens and its application
JP2019515874A (en) 2016-03-01 2019-06-13 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト Obintuzumab variants with altered cell death induction
WO2017149018A1 (en) 2016-03-02 2017-09-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and kits for predicting the risk of relapse in patients suffering from idiopathic nephrotic syndrome
US10336784B2 (en) 2016-03-08 2019-07-02 Academia Sinica Methods for modular synthesis of N-glycans and arrays thereof
WO2017160599A1 (en) 2016-03-14 2017-09-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of cd300b antagonists to treat sepsis and septic shock
MX2018011204A (en) 2016-03-15 2019-03-07 Mersana Therapeutics Inc Napi2b-targeted antibody-drug conjugates and methods of use thereof.
JP2019514870A (en) 2016-04-22 2019-06-06 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル Methods and vaccine compositions for the treatment of B cell malignancies
WO2017192874A1 (en) 2016-05-04 2017-11-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Albumin-binding immunomodulatory compositions and methods of use thereof
AU2017283470A1 (en) 2016-06-14 2019-01-03 Regeneron Pharmaceuticals, Inc. Anti-C5 antibodies and uses thereof
CN106267406B (en) * 2016-07-01 2019-02-01 翁炳焕 AIDS blood purification
US20190256599A1 (en) 2016-08-04 2019-08-22 Glaxosmithkline Intellectual Property Development Limited Anti-icos and anti-pd-1 antibody combination therapy
WO2018054484A1 (en) 2016-09-23 2018-03-29 Biontech Ag Bispecific trivalent antibodies binding to claudin 6 or claudin18.2 and cd3 for treatment of claudin expressing cancer diseases
US20190276549A1 (en) 2016-11-01 2019-09-12 Genmab B.V. Polypeptide variants and uses thereof
US20180154018A1 (en) 2016-11-23 2018-06-07 Mersana Therapeutics, Inc. Peptide-containing linkers for antibody-drug conjugates
WO2018099539A1 (en) 2016-11-29 2018-06-07 Horst Lindhofer Combination of t-cell redirecting multifunctional antibodies with immune checkpoint modulators and uses thereof
EP3548068A1 (en) 2016-12-01 2019-10-09 GlaxoSmithKline Intellectual Property Development Limited Combination therapy
WO2018100096A1 (en) 2016-12-01 2018-06-07 Inserm (Institut National De La Sante Et De La Recherche Medicale) Use of anti-uchl1 igg plasma concentration for diagnosing idiopathic steroid sensitive nephrotic syndrome
CA3045241A1 (en) 2016-12-01 2018-06-07 Glaxosmithkline Intellectual Property Development Limited Combination therapy
AU2017380981A1 (en) 2016-12-19 2019-05-02 F. Hoffmann-La Roche Ag Combination therapy with targeted 4-1BB (CD137) agonists
AU2017384126A1 (en) 2016-12-20 2019-05-02 F. Hoffmann-La Roche Ag Combination therapy of anti-CD20/anti-CD3 bispecific antibodies and 4-1BB (CD137) agonists
AU2018218345A1 (en) 2017-02-10 2019-08-29 Genmab B.V. Polypeptide variants and uses thereof
TW201834697A (en) 2017-02-28 2018-10-01 美商梅爾莎納醫療公司 Combination therapies of her2-targeted antibody-drug conjugates
WO2018167780A1 (en) 2017-03-12 2018-09-20 Yeda Research And Development Co. Ltd. Methods of prognosing and treating cancer
WO2018167778A1 (en) 2017-03-12 2018-09-20 Yeda Research And Development Co. Ltd. Methods of diagnosing and prognosing cancer
WO2018183929A1 (en) 2017-03-30 2018-10-04 Progenity Inc. Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
WO2018178396A1 (en) 2017-03-31 2018-10-04 Genmab Holding B.V. Bispecific anti-cd37 antibodies, monoclonal anti-cd37 antibodies and methods of use thereof
CN107446046A (en) * 2017-07-05 2017-12-08 无锡傲锐东源生物科技有限公司 Anti-cd20 monoclonal antibodies and uses thereof
WO2019020606A1 (en) 2017-07-26 2019-01-31 F. Hoffmann-La Roche Ag Combination therapy with a bet inhibitor, a bcl-2 inhibitor and an anti-cd20 antibody
WO2019048040A1 (en) 2017-09-06 2019-03-14 Ganymed Pharmaceuticals Gmbh Antibodies useful in cancer diagnosis
WO2019077123A1 (en) 2017-10-20 2019-04-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and kits for determining whether a subject has or is at risk of having of an autoimmune myopathy
WO2019104289A1 (en) 2017-11-27 2019-05-31 Mersana Therapeutics, Inc. Pyrrolobenzodiazepine antibody conjugates
WO2019115659A1 (en) 2017-12-14 2019-06-20 F. Hoffmann-La Roche Ag Use of a cea cd3 bispecific antibody and a pd-1 axis binding antagonist in a dosage regime to treat cancer
WO2019126691A1 (en) 2017-12-21 2019-06-27 Mersana Therapeutics, Inc. Pyrrolobenzodiazepine antibody conjugates
WO2019145455A1 (en) 2018-01-24 2019-08-01 Genmab B.V. Polypeptide variants and uses thereof
WO2019175113A1 (en) 2018-03-12 2019-09-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of caloric restriction mimetics for potentiating chemo-immunotherapy for the treatment of cancers
WO2019175125A1 (en) 2018-03-13 2019-09-19 F. Hoffmann-La Roche Ag Combination therapy with targeted 4-1bb (cd137) agonists
WO2019175071A1 (en) 2018-03-13 2019-09-19 F. Hoffmann-La Roche Ag Therapeutic combination of 4-1 bb agonists with anti-cd20 antibodies

Family Cites Families (111)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4474893A (en) 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
MX9203291A (en) 1985-06-26 1992-08-01 Liposome Co Inc Method for coupling liposomes.
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US5182368A (en) 1986-06-13 1993-01-26 Ledbetter Jeffrey A Ligands and methods for augmenting B-cell proliferation
US5247069A (en) 1986-06-13 1993-09-21 Oncogen Ligands and methods for augmenting B-cell proliferation
US4954617A (en) 1986-07-07 1990-09-04 Trustees Of Dartmouth College Monoclonal antibodies to FC receptors for immunoglobulin G on human mononuclear phagocytes
US4881175A (en) 1986-09-02 1989-11-14 Genex Corporation Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
IL85035D0 (en) * 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
US5013653A (en) 1987-03-20 1991-05-07 Creative Biomolecules, Inc. Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
DE3853515D1 (en) 1987-05-21 1995-05-11 Creative Biomolecules Inc Multifunctional proteins with predetermined goal setting.
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5506126A (en) 1988-02-25 1996-04-09 The General Hospital Corporation Rapid immunoselection cloning method
US6218525B1 (en) 1988-02-25 2001-04-17 The General Hospital Corporation Nucleic acid encoding CD28
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
CA2161351C (en) 1993-04-26 2010-12-21 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
KR100272077B1 (en) 1990-08-29 2000-11-15 젠팜인터내셔날,인코포레이티드 Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
WO1992022645A1 (en) 1991-06-14 1992-12-23 Genpharm International, Inc. Transgenic immunodeficient non-human animals
DE69224906T2 (en) 1991-07-08 1998-10-29 Univ Massachusetts Thermotropic liquid crystalline segment-block copolymer
US6136310A (en) 1991-07-25 2000-10-24 Idec Pharmaceuticals Corporation Recombinant anti-CD4 antibodies for human therapy
AT237638T (en) 1991-07-25 2003-05-15 Idec Pharma Corp Recombinant antibodies for human therapy
US5756096A (en) 1991-07-25 1998-05-26 Idec Pharmaceuticals Corporation Recombinant antibodies for human therapy
MX9204374A (en) 1991-07-25 1993-03-01 Idec Pharma Corp recombinant antibody and method for its production.
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US5540926A (en) 1992-09-04 1996-07-30 Bristol-Myers Squibb Company Soluble and its use in B cell stimulation
GB9223377D0 (en) 1992-11-04 1992-12-23 Medarex Inc Humanized antibodies to fc receptors for immunoglobulin on human mononuclear phagocytes
EP1005870B1 (en) 1992-11-13 2009-01-21 Biogen Idec Inc. Therapeutic application of chimeric antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US6096878A (en) 1993-05-10 2000-08-01 Japan Tobacco Inc. Human immunoglobulin VH gene segments and DNA fragments containing the same
US5595721A (en) 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
EP1709970A1 (en) 1995-04-27 2006-10-11 Abgenix, Inc. Human antibodies against EGFR, derived from immunized xenomice
US20010056066A1 (en) 1996-07-26 2001-12-27 Smithkline Beecham Corporation Method of treating immune cell mediated systemic diseases
JP2000516594A (en) 1996-07-26 2000-12-12 スミスクライン・ビーチャム・コーポレイション Improved treatment of immune cell-mediated systemic diseases
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US20020041847A1 (en) 1998-03-12 2002-04-11 Goldenberg David M. Immunotherapy of malignant and autoimmune disorders in domestic animals using naked antibodies, immunoconjugates and fusion proteins
US6306393B1 (en) 1997-03-24 2001-10-23 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
US6183744B1 (en) 1997-03-24 2001-02-06 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
JP2001516766A (en) 1997-09-19 2001-10-02 デイナ−ファーバー キャンサー インスティチュート,インコーポレイテッド Intrabodies mediated regulation of the immune reaction
CA2315977A1 (en) 1997-12-24 1999-07-08 Ludwig Institute For Cancer Research Expression vectors and cell lines expressing vascular endothelial growth factor d, and method of treating melanomas
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
AU5097099A (en) 1998-07-16 2000-02-07 Vincent Marinkovich Methods and compositions for cancer treatment
CA2399080C (en) 2000-02-03 2013-05-21 Millennium Pharmaceuticals, Inc. Humanized anti-ccr2 antibodies and methods of use therefor
CN101695574A (en) * 1998-08-11 2010-04-21 拜奥根Idec公司; Combination therapies for b-cell lymphomas comprising administration of anti-cd20 antibody
US20010033839A1 (en) 1999-10-04 2001-10-25 Emilio Barbera-Guillem Vaccine and immunotherapy for solid nonlymphoid tumor and related immune dysregulation
US6224866B1 (en) 1998-10-07 2001-05-01 Biocrystal Ltd. Immunotherapy of B cell involvement in progression of solid, nonlymphoid tumors
JP4842435B2 (en) 1998-11-09 2011-12-21 バイオジェン・アイデック・インコーポレイテッドBiogen Idec Inc. Treatment of hematological malignancies associated with circulating tumor cells using chimeric anti-CD20 antibodies
AU761516B2 (en) 1998-11-09 2003-06-05 Biogen Inc. Chimeric anti-CD20 antibody treatment of patients receiving BMT or PBSC transplants
DK1176981T3 (en) * 1999-05-07 2006-04-10 Genentech Inc Treating autoimmune diseases with antagonists that bind to B celleoverflademarkörer
PT1194167E (en) 1999-06-09 2009-10-23 Immunomedics Inc Immunotherapy of autoimmune disorders using antibodies which target b-cells
AU778863B2 (en) 1999-07-12 2004-12-23 Genentech Inc. Blocking immune response to a foreign antigen using an antagonist which binds to CD20
MXPA02000962A (en) 1999-07-29 2002-07-02 Medarex Inc Human monoclonal antibodies to her2 neu.
AU784971B2 (en) 1999-08-11 2006-08-10 Biogen Inc. Treatment of patients having non-Hodgkins lymphoma with bone marrow involvement with anti-CD20 antibodies
US8557244B1 (en) 1999-08-11 2013-10-15 Biogen Idec Inc. Treatment of aggressive non-Hodgkins lymphoma with anti-CD20 antibody
EP2829609A1 (en) 1999-08-24 2015-01-28 E. R. Squibb & Sons, L.L.C. Human CTLA-4 antibodies and their uses
US20020006404A1 (en) 1999-11-08 2002-01-17 Idec Pharmaceuticals Corporation Treatment of cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
US20020159996A1 (en) 2001-01-31 2002-10-31 Kandasamy Hariharan Use of CD23 antagonists for the treatment of neoplastic disorders
EP1370292A1 (en) 2001-01-31 2003-12-17 Idec Pharmaceuticals Corporation Use of cd23 antagonists for the treatment of neoplastic disorders
AU2001264612C1 (en) 1999-11-08 2007-11-22 Biogen Idec Inc. Treatment of B cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
EP1372724A2 (en) 2001-01-31 2004-01-02 Idec Pharmaceuticals Corporation Use of immunoregulatory antibodies in the treatment of neoplastic disorders
IL149500D0 (en) 1999-11-08 2002-11-10 Idec Pharma Corp Treatment of b cell malignancies using anti-cd40l antibodies in combination with anti-cd20 antibodies and/or chemotherapeutics and radiotherapy
EP1125905A1 (en) 2000-02-16 2001-08-22 Pepscan Systems B.V. Segment synthesis
AU4773701A (en) * 2000-03-24 2001-10-08 Chiron Corp Methods of therapy for non-hodgkin's lymphoma using a combination of an antibodyto cd20 and interleuking-2
MXPA02009523A (en) * 2000-03-30 2003-02-12 Amgen Inc CD20 IgE RECEPTOR LIKE MOLECULES AND USES THEREOF.
JP2004500412A (en) 2000-03-31 2004-01-08 アイデック ファーマスーティカルズ コーポレイション Anti-cytokine antibody or combination of antagonist and anti-cd20 for the treatment of B-cell lymphoma
US20020009444A1 (en) 2000-04-25 2002-01-24 Idec Pharmaceuticals Corporation Intrathecal administration of rituximab for treatment of central nervous system lymphomas
AU6836301A (en) 2000-06-20 2002-01-02 Idec Pharma Corp Treatment of b-cell associated diseases such as malignancies and autoimmune diseases using a cold anti-cd20 antibody/radiolabeled anti-cd22 antibody combination
AT440618T (en) 2000-06-22 2009-09-15 Univ Iowa Res Found Combination of CpG and antikírpern against CD19, CD20, CD22 or CD40 for the prevention or treatment of cancer.
US20020028178A1 (en) 2000-07-12 2002-03-07 Nabil Hanna Treatment of B cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
US20020048550A1 (en) 2000-07-20 2002-04-25 Vallera Daniel A. Radiolabeled immunotoxins
CA2422155A1 (en) 2000-08-03 2002-02-14 Wim Van Schooten Production of humanized antibodies in transgenic animals
MXPA03002262A (en) * 2000-09-18 2003-10-15 Idec Pharma Corp Combination therapy for treatment of autoimmune diseases using b cell depleting/immunoregulatory antibody combination.
WO2002034790A1 (en) 2000-10-20 2002-05-02 Idec Pharmaceuticals Corporation Variant igg3 rituxan r and therapeutic use thereof
AU3942202A (en) 2000-11-30 2002-06-11 Medarex Inc Transgenic transchromosomal rodents for making human antibodies
AU2002251692A1 (en) 2000-12-08 2002-08-19 Duke University Identification of novel ms4a gene family members expressed by hematopoietic cells
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
EP1383800A4 (en) 2001-04-02 2004-09-22 Idec Pharma Corp RECOMBINANT ANTIBODIES COEXPRESSED WITH GnTIII
EP1558648B1 (en) 2002-10-17 2012-01-11 Genmab A/S Human monoclonal antibodies against cd20
JP2011507897A (en) 2007-12-21 2011-03-10 ジェネンテック, インコーポレイテッド Treatment of rituximab-resistant patients with rheumatoid arthritis

Also Published As

Publication number Publication date
EP3284753B1 (en) 2019-06-05
AU2003301445A1 (en) 2004-05-04
BRPI0315295B8 (en) 2019-08-20
KR20110017020A (en) 2011-02-18
MXPA05004022A (en) 2005-10-05
KR20080090565A (en) 2008-10-08
JP2010042002A (en) 2010-02-25
KR20090088973A (en) 2009-08-20
PL376351A1 (en) 2005-12-27
EA201492217A1 (en) 2015-06-30
EP3284753A3 (en) 2018-03-14
KR101348472B1 (en) 2014-01-07
EP2316856B1 (en) 2017-08-09
EP1558648A2 (en) 2005-08-03
NZ568769A (en) 2010-04-30
JP5767041B2 (en) 2015-08-19
JP2012005485A (en) 2012-01-12
CN101928344A (en) 2010-12-29
BR0315295A (en) 2005-08-30
EP1558648A4 (en) 2006-02-15
US8529902B2 (en) 2013-09-10
ES2524694T3 (en) 2014-12-11
BRPI0315295B1 (en) 2018-12-26
CA3029035A1 (en) 2004-04-29
CN103709250A (en) 2014-04-09
KR100944575B1 (en) 2010-02-25
IL221193D0 (en) 2012-09-24
LU92041I2 (en) 2014-01-11
ES2380621T3 (en) 2012-05-16
JP5155968B2 (en) 2013-03-06
CN103709250B (en) 2016-08-10
KR100932340B1 (en) 2009-12-16
CN1729203A (en) 2006-02-01
CY1112750T1 (en) 2015-08-05
US20040167319A1 (en) 2004-08-26
CN1729203B (en) 2014-02-19
WO2004035607A3 (en) 2004-08-12
EP1558648B1 (en) 2012-01-11
KR20120128151A (en) 2012-11-26
CA2502552C (en) 2019-02-12
IL167851A (en) 2013-12-31
KR20100050587A (en) 2010-05-13
US20140093454A1 (en) 2014-04-03
WO2004035607A2 (en) 2004-04-29
PL402418A1 (en) 2013-05-27
EA021644B1 (en) 2015-08-31
HK1077590A1 (en) 2012-08-10
EP3284753A2 (en) 2018-02-21
CA2502552A1 (en) 2004-04-29
EP2316856A1 (en) 2011-05-04
DK1558648T3 (en) 2012-04-23
CN101928344B (en) 2014-08-13
LU92041I9 (en) 2019-01-03
KR20050049552A (en) 2005-05-25
SI1558648T1 (en) 2012-05-31
NZ581541A (en) 2011-07-29
IL167851D0 (en) 2009-02-11
EP2330130B1 (en) 2014-08-27
PL216630B1 (en) 2014-04-30
KR20110140142A (en) 2011-12-30
JP4662473B2 (en) 2011-03-30
EA200500679A1 (en) 2006-02-24
PT1558648E (en) 2012-04-23
WO2004035607A8 (en) 2004-06-17
EP2330130A1 (en) 2011-06-08
PL218660B1 (en) 2015-01-30
JP2006507844A (en) 2006-03-09

Similar Documents

Publication Publication Date Title
DE60143798D1 (en) Immune specific binding antibodies against BLyS
DE60336044D1 (en) seat slide
AT370832T (en) Rapid prototyping device
DE60222471D1 (en) radar device
AT455436T (en) Distributed real-time media-composer
DE50309901D1 (en) microtome
AT554107T (en) As therapeutics suitable monovalent antibody fragments
DE60329522D1 (en) image analysis
AT529660T (en) damper mechanism
DE602004013327D1 (en) Solemnity aluminiumlegierungshartlötblech
DE60323810D1 (en) convenient diaper
DE60200515D1 (en) closure device
NO20054078D0 (en) Human antibodies specific for Interleukin 15 (IL15).
DK2138512T3 (en) Humanized anti-NGF antibodies
AT384744T (en) Human antibody against HER2 / neu
DE60326855D1 (en) output device
AT439899T (en) screening device
DE60329489D1 (en) Fusion proteins humanized G250 specific antibody and uses thereof
AT510561T (en) Kdr-specific human antibodies and their use
DE60325564D1 (en) Biospecific contrast agents
AT541590T (en) Modified antibody-fragments
DE60321740D1 (en) toner
AT500274T (en) Human antibody molecules for il-13
DE60142500D1 (en) Human monoclonal antibodies against the costimulatory signal transduction AILIM and pharmaceutical uses thereof
AT534987T (en) Presence and geographical place-alert